title: Etoposide and cisplatin salvage chemotherapy for small cell lung cancer.
abstract: Thirty patients with previously treated small cell lung cancer received salvage combination chemotherapy with etoposide and cisplatin. Two complete and six partial responses were observed, for a major response rate of 27%. Responses occurred promptly and sustained palliation was achieved among responders. Myelosuppression was the major dose-limiting toxic effect. A schedule of etoposide (115 mg/m2 iv on Days 1-3) and cisplatin (25 mg/m2 iv on Days 1-3 every 28 days) is recommended for further clinical trials.
authors.forename: J A
authors.initials: JA
authors.lastname: Lopez
authors.forename: J
authors.initials: J
authors.lastname: Mann
authors.forename: R T
authors.initials: RT
authors.lastname: Grapski
authors.forename: E
authors.initials: E
authors.lastname: Nassif
authors.forename: P
authors.initials: P
authors.lastname: Vannicola
authors.forename: J G
authors.initials: JG
authors.lastname: Krikorian
authors.forename: H
authors.initials: H
authors.lastname: Finkel
mesh_terms: D000368:Aged; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005047:Etoposide / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010976:Platelet Count; D011034:Podophyllotoxin / Q000031:analogs & derivatives*
chemical_list: D005047:Etoposide; D011034:Podophyllotoxin; D002945:Cisplatin